Schistosomiasis Pipeline Featuring 3+ Companies Expected to Change the Pace of the Schistosomiasis Treatment

"The infectious form of the parasite, known as cercariae, emerge from the snail into the water. You can become infected when your skin comes in contact with contaminated freshwater. Most human infections are caused by Schistosoma mansoni, S. haematobium, or S. japonicum"

The drug is described in detail in the Schistosomiasis pipeline report, along with its mechanism of action, Schistosomiasis clinical trials, Schistosomiasis NDA approvals (if any), and product development activities that include technology, Schistosomiasis collaborations, licensing, mergers and acquisitions, funding, designations, and other product-related information.

DelveInsight's, "Schistosomiasis Pipeline Insight, 2023," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Schistosomiasis pipeline landscape. It covers the Schistosomiasis pipeline drug profiles, including Schistosomiasis clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Schistosomiasis Pipeline Report

• The Schistosomiasis pipeline report from DelveInsight shows a healthy market with 3+ Companies actively working on 3+ pipeline therapies for the Schistosomiasis treatment.

• The leading Schistosomiasis Companies include Merck, Orygen Biotecnologia, Ocean Biomedical, BioDiem, Pharco Pharmaceuticals, Merck, Hikma Pharmaceuticals LLC, Dafra Pharma, and others.

• Promising Schistosomiasis Pipeline Therapies include Praziquantel 600Mg Oral Tablet x 1, Artesunate+Sulfamethoxypyrazine/pyrimethamin, Biltricide, L-PZQ ODT, Myrrh, and others.

• The Schistosomiasis Companies and academics are working to assess challenges and seek opportunities that could influence Schistosomiasis R&D. The Schistosomiasis pipeline therapies under development are focused on novel approaches to treat/improve Schistosomiasis.

Request a sample and discover the recent advances in Schistosomiasis Drug Treatment @ Schistosomiasis Pipeline Report- https://www.delveinsight.com/sample-request/schistosomiasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Schistosomiasis Overview
Schistosomiasis, also known as bilharzia, is a disease caused by parasitic worms. Although the worms that cause schistosomiasis are not found in the United States, people are infected worldwide. In terms of impact this disease is second only to malaria as the most devastating parasitic disease. Schistosomiasis is considered one of the neglected tropical diseases (NTDs).The parasites that cause schistosomiasis live in certain types of freshwater snails.

Schistosomiasis Emerging Drugs Profile

• Praziquantel paediatric formulation: Merck
Praziquantel paediatric formulation is being developed by Pediatric Praziquantel Consortium in association with Merck. A confirmatory Phase III trial is ongoing in Côte d'Ivoire and Kenya. This study is an open-label, efficacy and safety trial of Levo-Praziquantel 150mg in Schistosoma-infected children 3 months to 6 years of age, including a 2:1 randomized, controlled cohort of Schistosoma mansoni-infected children 4 to 6 years of age treated with L-PZQ ODT or commercial praziquantel.

• Sm 14: Orygen Biotecnologia
Sm 14, a recombinant fatty acid binding protein (FABP) antigen vaccine for the treatment of Schistosomiasis. Currently, it is in phase II stage of clinical trial evaluation.

Learn more about the emerging Schistosomiasis pipeline therapies @ Schistosomiasis Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/schistosomiasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Schistosomiasis Pipeline Therapeutics Assessment
There are approx. 3+ key companies which are developing the therapies for Schistosomiasis. The companies which have their Schistosomiasis drug candidates in the most advanced stage, i.e. phase III include, Merck.

Schistosomiasis Pipeline Segmentation: Phases
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Schistosomiasis Route of Administration
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical.
• Molecule Type

Schistosomiasis Molecule Types
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Learn more about the emerging Schistosomiasis pipeline therapies @ Schistosomiasis Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/schistosomiasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Schistosomiasis Pipeline Report

• Coverage- Global

• Schistosomiasis Companies- Merck, Orygen Biotecnologia, Ocean Biomedical, BioDiem, Pharco Pharmaceuticals, Merck, Hikma Pharmaceuticals LLC, Dafra Pharma, and others.

• Schistosomiasis Pipeline Therapies- Praziquantel 600Mg Oral Tablet x 1, Artesunate+Sulfamethoxypyrazine/pyrimethamin, Biltricide, L-PZQ ODT, Myrrh, and others.

• Schistosomiasis Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Dive deep into rich insights for drugs for Schistosomiasis Market Drivers and Schistosomiasis Market Barriers, click here @ Schistosomiasis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/schistosomiasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Schistosomiasis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Schistosomiasis - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Schistosomiasis Collaboration Deals
9. Late Stage Products (Phase III)
10. Praziquantel paediatric formulation: Merck
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Sm 14: Orygen Biotecnologia
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Schistosomiasis Key Companies
17. Schistosomiasis Key Products
18. Schistosomiasis- Unmet Needs
19. Schistosomiasis- Market Drivers and Barriers
20. Schistosomiasis- Future Perspectives and Conclusion
21. Schistosomiasis Analyst Views
22. Schistosomiasis Key Companies
23. Appendix

Got Queries? Find out the related information on Schistosomiasis Mergers and acquisitions, Schistosomiasis Licensing Activities @ Schistosomiasis Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/schistosomiasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.